Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Variations in the latitudinal diversity gradients of the ocean microbiome.

Cell host & microbe·2026
Same author

microntology: a lightweight, data-driven controlled vocabulary to describe earth's microbial habitats.

Bioinformatics (Oxford, England)·2026
Same author

Molecular maps of diseases from omics data and network embeddings.

NPJ systems biology and applications·2026
Same author

CCMRI: a classification and curated database of climate change-related microbiome studies.

Scientific reports·2026
Same author

Estimating the economic burden of lower respiratory infections in China from 2020 to 2040: a health-augmented macroeconomic modelling study.

The Lancet regional health. Western Pacific·2026
Same author

Alcohol-related liver disease disrupts bile acid homeostasis and gut microbial bile acid metabolism.

JHEP reports : innovation in hepatology·2026

相关实验视频

Updated: Jul 3, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

使用副作用相似性的药物标识.

Monica Campillos1, Michael Kuhn, Anne-Claude Gavin

  • 1European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.

Science (New York, N.Y.)
|July 16, 2008
PubMed
概括

这项研究表明,药物的副作用可以预测共享的药物点,即使是化学上不相似的药物. 这种方法可以识别新的药物向相互作用以及现有药物的潜在新疗法用途.

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 计算生物学 计算生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • 传统的药物标预测依赖于分子或细胞特征,如化学结构或细胞系活动.
  • 识别共享的药物点对于理解药物机制和重新定位药物至关重要.

研究的目的:

  • 调查表型副作用相似性对于推断共享药物点的有用性.
  • 通过对市场药物的大规模分析,发现新的药物药物关系和潜在的药物向相互作用.

主要方法:

  • 在746种已上市的药物中利用表型副作用的相似性来构建药物药物关系网络.
  • 通过实验验证预测的药物药物关系和暗示的药物标相互作用,使用体外结合和基于细胞的测定.

主要成果:

  • 确定了一个由1018种副作用驱动的药物与药物关系组成的网络,其中包括261种涉及不同治疗领域的化学上不相似的药物.
  • 实验验证了13个暗示的药物标关系,其中11个显示抑制常量低于10微米.
  • 在基于细胞的测定中证实了这些相互作用中的九个,证明了表型方法的可行性.

结论:

  • 表型副作用相似性是推断分子相互作用和共享药物点的可行策略.

更多相关视频

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

相关实验视频

Last Updated: Jul 3, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

  • 这种方法成功地发现了意想不到的药物药物关系,并验证了新的药物向相互作用.
  • 这些发现表明,现有市场药物的潜在新疗法应用.